Pulmatrix, Inc. - PULM STOCK NEWS

Pulmatrix, Inc. (NASDAQ: PULM) announced it will regain full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, after Johnson & Johnson's decision to terminate their licensing agreement. Ongoing clinical studies for PUR1800 in treating acute exacerbations of COPD (AECOPD) are progressing, with expected topline data in Q4 2021. A Phase 2 efficacy study is planned for 2022. Notably, toxicology studies indicate favorable outcomes, enhancing the potential for long-term dosing applications. The market potential for PUR1800 could reach approximately $2.5 billion in the U.S.

Pulmatrix, Inc. (NASDAQ: PULM) has regained full rights to its narrow spectrum kinase inhibitor (NSKI) portfolio, including PUR1800, following the termination of its agreement with Johnson & Johnson. The company plans to advance PUR1800's development with ongoing clinical and toxicology studies for treating acute exacerbations in COPD and other chronic airway diseases. The recent studies show promising results, indicating potential long-term dosing benefits. Pulmatrix anticipates topline data from its Phase 1b clinical study in Q4 2021 and expects a Phase 2b efficacy study to begin later this year.

Pulmatrix, Inc. (NASDAQ: PULM) reported its Q4 and full year 2020 financial results, showing a revenue increase to $12.6 million from $7.9 million in 2019. The company completed a registered direct offering, raising $40 million to fund ongoing studies including the PUR1800 Phase 1b. Notable studies include the initiation of the Phase 1b for PUR1800, expected data release in Q4 2021, and efforts for the Pulmazole Phase 2b study. The net loss for 2020 was $19.3 million, largely driven by project costs related to Pulmazole and PUR1800.

Pulmatrix, Inc. (NASDAQ: PULM) provides an update on its clinical pipeline and financing. The company has dosed 3 out of 15 patients in a Phase 1b trial for PUR1800, with top-line data expected in Q4 2021. It plans to initiate a Phase 2b study for Pulmazole in Q1 2022, pending committee approval. PUR3100 showed promising results in a dog study, aiming for a Phase 1/2 trial start in Q1 2022. Additionally, Pulmatrix completed a direct offering with $40 million in proceeds, strengthening its financial position for ongoing studies.

Pulmatrix, a clinical stage biopharmaceutical company, has successfully completed a registered direct offering, selling 20 million shares at a gross amount of $40 million. The offering was facilitated by H.C. Wainwright & Co. The net proceeds are intended for working capital and general corporate purposes. This transaction follows the registration under Form S-3 with the SEC, initially filed in March 2019. Pulmatrix focuses on developing inhaled therapies for serious diseases, including treatments for lung conditions like allergic bronchopulmonary aspergillosis and lung cancer.

Pulmatrix (NASDAQ: PULM) has entered into agreements for a registered direct offering of 20 million shares at $2.00 per share, aiming to raise $40 million before expenses. The closing is expected around February 16, 2021, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The funds will support working capital and general corporate purposes. The offering is made under a previously filed shelf registration statement with the SEC, ensuring compliance with regulatory requirements.

Pulmatrix, Inc. (NASDAQ: PULM) reported its Q3 2020 financial results, showcasing a revenue increase to $4.4 million, up from $1.4 million in Q3 2019. The company had $34.5 million in cash as of September 30, 2020. Pulmatrix plans to advance multiple programs, including the anticipated clinical trial of PUR1800 in early 2021, targeting lung cancer. Additionally, the launch of FEND, an OTC nasal hygiene product, provides potential for escalating royalties. However, net loss increased to $10.6 million, attributed to warrant inducement expenses and costs related to clinical studies.

Pulmatrix, Inc. (NASDAQ: PULM) announced the commercial launch of FEND, a nasal mister product designed to combat COVID-19 by reducing respiratory droplets. Developed in partnership with Sensory Cloud, FEND incorporates Pulmatrix's proprietary NasoCalm formulations. Clinical studies show that FEND can lower exhaled aerosol particles by up to 99% for six hours. With expected escalating royalties from sales, the launch may provide additional revenue to support Pulmatrix's iSPERSE™ technology for inhaled therapies focused on serious lung diseases.

On September 30, 2020, Pulmatrix (NASDAQ: PULM) announced data from partner Sensory Cloud showcasing the efficacy of FEND, a nasal mist product, in reducing bioaerosol generation. The study revealed that FEND reduced exhaled particles by approximately 75%, outperforming surgical masks. The publication was co-authored by notable researchers including Dr. David Edwards and Dr. Robert Langer. Pulmatrix licensed its NasoCalm formulations to Sensory Cloud, which will market FEND and provide Pulmatrix with escalating royalties upon sales commencement.